GAITHERSBURG, Md., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, president and chief executive officer of Altimmune, will present a corporate overview at the 29th Annual Piper Jaffray Conference, taking place November 28-29, 2017 in New York, NY.
||November 28, 2017
||2:00pm Eastern Standard Time
||Lotte New York Palace Hotel; New York, NY
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease and on the development of two next-generation anthrax vaccines that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. The company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines.
President and CEO
Managing Director LifeSci Advisors
Source: Altimmune, Inc.